Antidote passes from development phase to acceptance phase of pharmaceutical companies, allow it to be mass-produced, commercialised
The Israel Institute for Biological Research (IIBR) and the Israeli Ministry of Defense announced that the development phase of an antibody that would be effective in neutralising SARS-Cov-2, known as the Coronavirus, has been completed.
Through its Twitter account, the Israeli Ministry of Defense confirmed the development of what could become the first antidote to COVID-19.
According to the entities, now the antidote passes from the development phase to the acceptance phase of the pharmaceutical companies, which would allow it to be mass-produced and commercialised.
The scientific development would be made up of a few proteins that are harmful to the human body and has already been tested on patients with risky cases of Coronavirus.
Israel claim that the IIBR is the first institution to achieve a scientific breakthrough that meets all three parameters:
- A new and refined monoclonal antibody containing a deficient proportion of harmful proteins
- The antibody can neutralise the Coronavirus
- The antibody was explicitly tested in aggressive cases of Coronavirus
In the meantime, the Government of Israel announced the complete removal of mobility restrictions imposed on citizens.